[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peanut-allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peanut-allergies":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,70,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100637208","bhlmann-bat-basophil-activation-test-in-allergy-diagnosis-exploratory-pilot-study-100637208",false,"NCT07596303","BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)","Exploratory Pilot Study of BÜHLMANN Automated Basophil Activation Test as an Aid to Diagnosis of Immediate Type Allergic Disorders","Inclusion Criteria:\n\n* Individuals with diagnosis of a hypersensitivity \u002F allergy to one of the 6 allergens, established according to common clinical practice\n\nExclusion Criteria:\n\n* Pregnant women\n* Children under the age of 18 months\n* Individuals under therapy with Omalizumab or Rituximab\n* Individuals with an allergic reaction less than two weeks before blood sample collection\n* Individuals under therapy with BTK inhibitors\n* Individuals receiving allergen specific immunotherapy (ASIT)\n* Subjects with active infection and inflammatory conditions\n* Patients who are unable to understand the study information and informed consent form in German","ALL","18 Months",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay. The main questions it aims to answer are:\n\nDoes the BAT assay use the optimal allergen concentrations for stimulation, and how do its preliminary cut-offs perform in a real-world clinical scenario?\n\nParticipants older than 1.5 years who are being evaluated for possible allergy sensitization will provide one additional blood tube during their routine blood draw as part of the regular medical care. The study involves only one visit and does not provide direct personal benefit.",[24,25,26,27,28,29],"Allergy Testing","Peanut Allergies","Venom Allergy","House Dust Mite Allergy","Hazelnut Allergy","Cat Epithelium Allergy","RECRUITING","2026-05-28",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":20},"2026-05",{"date":38,"type":20},"2026-08-31",{"name":40,"class":41},"Bühlmann Laboratories AG","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100615010","phase-1-study-to-evaluate-the-safety-pharmacokinetic-and-pharmacodynamic-effects-of-my006-in-healthy-volunteers-and-patients-with-peanut-allergy-100615010","NCT07287033","Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy","A Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients With Peanut Allergy","Key Inclusion Criteria:\n\nPart A - Single-ascending dose and multiple dose cohorts in healthy volunteers\n\n1. Subject is male or female between 18 to 55 years of age, inclusive, at the screening visit.\n2. Subject agrees voluntarily to participate, and is able to read and understand, and willing to sign, the Institutional Review Board\u002FIndependent Ethics Committee-approved informed consent form prior to performing any screening visit procedures.\n3. Subject weight at screening and admission is between 45 kg and 100 kg, inclusive.\n4. Subject has a body mass index between 18.0 and 30.0 kg\u002Fm2, inclusive, at screening visit.\n\nPart B - Peanut-allergic patient cohorts\n\n1. Participant and\u002For parent\u002Flegal guardian must be able to understand and provide informed consent and\u002For assent, as applicable.\n2. Patient is male or female between 12 to 55 years of age, inclusive, at the screening visit.\n3. Patient weight at screening and admission is between 40 kg and 100 kg, inclusive.\n4. If patient is 12-17 years of age, their body mass index (BMI) must be above the 5th percentile and below the 95th percentile for age and sex at the screening visit. If patient is 18 years of age or above, their BMI must be between 18.0 and 30.0 kg\u002Fm2, inclusive, at the screening visit.\n5. Patient has a history of allergy to peanut and meets all of the following criteria:\n\n   1. Positive skin prick test (≥5 mm wheal greater than Placebo) to peanut; and\n   2. Positive specific IgE (≥0.7 kUA\u002FL) to peanut and Ara h 2 at screening determined by ImmunoCap; and\n   3. Positive double-blinded challenge to peanut during the screening period, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg of peanut protein.\n6. Patient is willing and able to avoid peanut-containing products and any other allergy-inducing foods known to the patient for the duration of study participation.\n\nKey Exclusion Criteria:\n\nPart A - Single-ascending dose and multiple dose cohorts in healthy volunteers\n\n1. Subject has a clinically relevant history, as determined by the Principal Investigator or designee, or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, and\u002For connective tissue diseases or disorders.\n2. Subject has clinically significant abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:\n\n   1. Systolic blood pressure ≥140 mmHg;\n   2. Diastolic blood pressure ≥90 mmHg; and\u002For\n   3. Heart rate ≥90 beats per minute.\n3. Subject has any clinically significant abnormalities in rhythm, conduction, or morphology of the resting electrocardiogram (ECG) and\u002For any clinically significant abnormalities in the 12-lead ECG as considered by the Principal Investigator or designee that may interfere with the interpretation of QTc interval changes.\n4. Subject has history of severe allergy\u002Fhypersensitivity, ongoing clinically significant allergy\u002Fhypersensitivity, as judged by the Principal Investigator or designee, known or suspected allergy to peanuts, and\u002For history of hypersensitivity to drugs with a similar structure or class.\n\nPart B - Peanut-allergy patient cohorts\n\n1. Patient has history of frequent or recent severe, life-threatening episodes of anaphylaxis or anaphylactic shock to peanut, as defined by more than 3 episodes of anaphylaxis within the past year and\u002For an episode of anaphylaxis within 60 days of screening.\n2. Patient has uncontrolled or severe asthma\u002Fwheezing at screening, defined by one or more of the following criteria:\n\n   1. Global Initiative for Asthma criteria regarding asthma control per latest guidelines;\n   2. History of two or more systemic corticosteroid courses within 6 months of screening or one course of systemic corticosteroids within three months of screening to treat asthma\u002Fwheezing;\n   3. Prior intubation\u002Fmechanical ventilation for asthma\u002Fwheezing;\n   4. One hospitalization or emergency department visit for asthma\u002Fwheezing within 12 months of screening;\n   5. Inhaled corticosteroid (ICS) dosing of \\>500 mcg daily fluticasone (or equivalent ICS based on the CoFAR Inhaled Corticosteroid Equivalency Tables); and\u002For\n   6. Forced expiratory volume in one second (FEV1) \\\u003C80% of predicted or FEV1\u002Fforced vital capacity \\\u003C75%, with or without controller medications.\n3. Patient has unstable exacerbated atopic disease (e.g., atopic dermatitis, urticaria, allergic rhinitis) defined by an episode of disease requiring initiation of systemic immunosuppressive or immunomodulatory treatment in the last 3 months.\n4. Patient has current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal, or metabolic dysfunction unless currently controlled and stable as judged by the Principal Investigator.\n5. Patient has abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:\n\n   1. Systolic blood pressure ≥140 mmHg;\n   2. Diastolic blood pressure ≥90 mmHg; and\u002For\n   3. Heart rate ≥90 beats per minute.",true,"12 Years","55 Years",{"count":54,"type":20},48,"INTERVENTIONAL",[57],"PHASE1","The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged acceptable, the second part of the study will be started. In the second part of the study, adult and adolescent participants with peanut allergy receive one dose of MY006 or a placebo, administered by subcutaneous injection. Several weeks later, the participants are given a food peanut challenge to assess reactions and treatment effects. The duration of the study for participants is for up to 32 weeks.",[25],"2026-05-05",{"date":62,"type":34},"2026-05-06",{"date":64,"type":34},"2025-12-06",{"date":66,"type":20},"2027-04",{"name":68,"class":41},"Mabylon AG",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100620558","a-long-term-observational-follow-up-study-of-children-and-young-people-who-underwent-an-18-month-course-of-oral-immunotherapy-treatment-for-peanut-egg-or-milk-allergy-5-15-years-post-treatment-100620558","NCT07359183","A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)","Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)","LPEM","Inclusion Criteria:\n\n* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study\n* Received at least one dose of OIT treatment in the parent study\n* Written informed consent from participant and\u002For parent\u002Fguardian (if below 18 years of age)\n\nExclusion Criteria:\n\n-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety",{"count":79,"type":20},147,"The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to:\n\n• Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not.\n\nParticipants will attend a single follow-up visit for:\n\n* A blood test\n* Skin prick test (SPT)\n* Allergy questionnaires",[82,25,83,84],"Food Allergies","Egg Allergy","Milk Allergy","2026-01-29",{"date":87,"type":34},"2026-02-02",{"date":89,"type":34},"2026-01-13",{"date":91,"type":20},"2027-01",{"name":93,"class":94},"Murdoch Childrens Research Institute","OTHER",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":50,"sex":16,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100223945","blood-samples-for-the-study-of-peanut-tree-nut-and-other-food-allergies-100223945","NCT02192866","Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies","Inclusion Criteria:\n\nThis protocol is to draw blood for a variety of related studies of food allergy. For this reason, we will list each group of subjects and the inclusion criteria for that group.\n\n1. De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.\n\n   * Inclusion criteria:\n\n     1. patients have been enrolled in a controlled trial of OIT for peanuts, and had at least one oral challenge.\n     2. Age 1-75.\n2. De-identified samples from patients who are undergoing clinically indicated food challenges for peanut allergy.\n\n   * Inclusion criteria:\n\n     1. concern regarding possible allergy to peanuts,\n     2. age 1-75,\n     3. plan to undergo a clinically indicated challenge with peanuts.\n3. Patients with peanut allergy.\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to peanuts,\n     2. age 6-75.\n4. Patients with other food allergies (especially tree nuts).\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to tree nuts or other foods,\n     2. age 6-75.\n5. Normal controls.\n\n   * Inclusion criteria:\n\n     1. no known food allergies,\n     2. recent ingestion of peanuts without difficulty, and\n     3. age 6-75.\n\nExclusion Criteria:\n\n1. Any known significant medical or psychiatric diagnosis\n2. Use of an investigational drug within 30 days\n3. Use of omalizumab (anti-IgE; Xolair) within 6 months","1 Year","75 Years",{"count":104,"type":20},270,"Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies. The blood collected will be used to answer questions and find information about peanut and other food allergies.\n\nSamples will come from:\n\n* People signed up by the investigators at the University of Colorado Denver\n* University of North Carolina, Massachusetts General Hospital, Children's Hospital of Colorado and the Immune Tolerance Network (Benaroya Research Institute) where people have been treated for peanut allergies\n* University of North Carolina, Massachusetts General Hospital, National Jewish Health and The Children's Hospital in Denver where people have taken part or will take part in clinically indicated oral food challenges.\n\nBlood and health histories from the University of North Carolina, Massachusetts General Hospital, National Jewish Health, The Children's Hospital and the Immune Tolerance Network will not have personal information linked.\n\nThe specific aims of this experiment are:\n\n1. Come up with a lab test that will predict how bad an allergic reaction will be to peanuts.\n2. Find out what part of a peanut causes allergic reactions.\n3. Come up with preventions that can block peanut allergies.\n4. Find the strongest proteins in walnuts.",[25,107,108],"Tree Nut Allergies","Other Food Allergies","2022-12-14",{"date":111,"type":34},"2022-12-19",{"date":113,"type":34},"2014-02",{"date":115,"type":20},"2030-12",{"name":117,"class":94},"University of Colorado, Denver"]